sb 203580 has been researched along with celecoxib in 5 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (celecoxib) | Trials (celecoxib) | Recent Studies (post-2010) (celecoxib) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 5,273 | 843 | 2,428 |
Protein | Taxonomy | sb 203580 (IC50) | celecoxib (IC50) |
---|---|---|---|
Chain A, Carbonic anhydrase II | Homo sapiens (human) | 0.021 | |
Prostaglandin E synthase | Homo sapiens (human) | 0.4825 | |
Histone deacetylase 3 | Homo sapiens (human) | 1.637 | |
Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 7.9667 | |
Prostaglandin G/H synthase 2 | Bos taurus (cattle) | 0.057 | |
Cytochrome c oxidase subunit 1 | Ovis aries (sheep) | 6.5 | |
Cytochrome c oxidase subunit 2 | Ovis aries (sheep) | 0.0881 | |
Catechol O-methyltransferase | Mus musculus (house mouse) | 0.036 | |
Cytochrome c oxidase subunit 2 | Homo sapiens (human) | 0.371 | |
Carbonic anhydrase 1 | Homo sapiens (human) | 0.1555 | |
Carbonic anhydrase 2 | Homo sapiens (human) | 0.0925 | |
Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 5.271 | |
Procathepsin L | Homo sapiens (human) | 0.56 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 7.308 | |
Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 0.07 | |
Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 4.295 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 1 | |
Cytochrome P450 2C9 | Homo sapiens (human) | 10 | |
Calpain-2 catalytic subunit | Homo sapiens (human) | 0.002 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 1.516 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.12 | |
Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | 3.6401 | |
Prostaglandin G/H synthase 1 | Homo sapiens (human) | 3.5499 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 7.308 | |
Indoleamine 2,3-dioxygenase 1 | Mus musculus (house mouse) | 0.006 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 6.276 | |
Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.3818 | |
Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.4028 | |
Urotensin-2 receptor | Rattus norvegicus (Norway rat) | 7.6 | |
Histone deacetylase 4 | Homo sapiens (human) | 1.637 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.03 | |
Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.6343 | |
Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 7.7 | |
Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.431 | |
Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.045 | |
Histone deacetylase 1 | Homo sapiens (human) | 1.411 | |
Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.81 | |
Carbonic anhydrase 9 | Homo sapiens (human) | 0.016 | |
Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | 0.05 | |
Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | 0.3 | |
Prostaglandin G/H synthase 1 | Canis lupus familiaris (dog) | 5.57 | |
Cyclooxygenase-2 | Canis lupus familiaris (dog) | 0.9 | |
Histone deacetylase 7 | Homo sapiens (human) | 1.637 | |
Histone deacetylase 2 | Homo sapiens (human) | 1.637 | |
Carbonic anhydrase 4 | Bos taurus (cattle) | 0.2227 | |
Polyamine deacetylase HDAC10 | Homo sapiens (human) | 1.637 | |
Histone deacetylase 11 | Homo sapiens (human) | 1.637 | |
Histone deacetylase 8 | Homo sapiens (human) | 1.637 | |
P2Y purinoceptor 12 | Rattus norvegicus (Norway rat) | 0.04 | |
Histone deacetylase 6 | Homo sapiens (human) | 1.14 | |
Histone deacetylase 9 | Homo sapiens (human) | 1.637 | |
Histone deacetylase 5 | Homo sapiens (human) | 1.637 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barreiro, EJ; Fraga, CA; Lima, LM; Sant'Anna, CM; Sperandio da Silva, GM | 1 |
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Jang, JH; Surh, YJ | 1 |
Hur, DY; Jin, DH; Kim, D; Kim, JE; Kim, S; Kim, YS; Lee, JI; Lee, WJ; Park, GB; Wu, TC | 1 |
5 other study(ies) available for sb 203580 and celecoxib
Article | Year |
---|---|
The molecular basis for coxib inhibition of p38alpha MAP kinase.
Topics: Algorithms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Databases, Factual; Enzyme Activation; Enzyme Inhibitors; p38 Mitogen-Activated Protein Kinases; Prostaglandin-Endoperoxide Synthases; Protein Binding; Quantitative Structure-Activity Relationship | 2005 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Beta-amyloid-induced apoptosis is associated with cyclooxygenase-2 up-regulation via the mitogen-activated protein kinase-NF-kappaB signaling pathway.
Topics: Amyloid beta-Peptides; Animals; Apoptosis; Butadienes; Celecoxib; Cyclooxygenase 2; Dinoprostone; Extracellular Signal-Regulated MAP Kinases; Imidazoles; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; NF-kappa B; Nitriles; p38 Mitogen-Activated Protein Kinases; PC12 Cells; Peptide Fragments; Poly(ADP-ribose) Polymerases; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Rats; Sulfonamides; Up-Regulation | 2005 |
Sequential treatment of HPV E6 and E7-expressing TC-1 cells with bortezomib and celecoxib promotes apoptosis through p-p38 MAPK-mediated downregulation of cyclin D1 and CDK2.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclooxygenase 2 Inhibitors; Down-Regulation; Endoplasmic Reticulum Stress; Female; G1 Phase Cell Cycle Checkpoints; Imidazoles; Mice; Mice, Inbred C57BL; Oncogene Proteins, Viral; p38 Mitogen-Activated Protein Kinases; Papillomavirus E7 Proteins; Pyrazines; Pyrazoles; Pyridines; Repressor Proteins; STAT3 Transcription Factor; Sulfonamides; Transcription Factor CHOP; Uterine Cervical Neoplasms | 2014 |